FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXNGAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectivelyYear-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billionCompany updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance
Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.
FRANKLIN LAKES, N.J., July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on September 30, 2026, to holders of record on September 9, 2026. The indicated annual dividend rate is $4.20 per share.
FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter. The news release and related presentation materials will be made available at www.bd.com/investors.
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety
